HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Executive Summary

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

You may also be interested in...



Dr Reddy’s Enters OTC Eyecare Space

Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.

French Experts Call For Mass Vitamin D Supplementation To Fight COVID-19

With around half the French population vitamin D deficient, a group of medical experts say mass supplementation is a low cost and low risk intervention which could save lives and curb the spread of COVID-19.

Viagra Connect To Launch In Ireland Following Rx-to-OTC Switch

Viagra will soon be available OTC in Ireland following a successful switch, but patients will have to complete a mandatory consultation with a pharmacist before the ED treatment can be supplied.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel